Brent Harwood, DPM
Foot & Ankle Surgery · Montrose, ALNPI 1609869536
Payments from drug & device makers
What this record shows
This record is dominated by education: $4,114 of the $6,703 with a category attached, or 61.4%. Prime Surgical, LLC accounts for 64.2% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $4,132 and has fallen 67.1% since, to $1,358 in 2025.
Across 23 payments — averaging $291.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Prime Surgical, LLC$4K
- CGG Medical Inc$1K
- Arthrex$721
- Organogenesis Inc.$182
- Musculoskeletal Transplant Foundation Inc.$147
- Stryker$111
- plus $35 from 2 others
What the payments were for
- Travel & lodging$1,81627%
- Food & beverage$77312%
- Education$4,11461%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Prime Surgical, LLC | 7 | $4,300 |
| CGG Medical Inc | 1 | $1,207 |
| Arthrex | 4 | $721 |
| Organogenesis Inc. | 3 | $182 |
| Musculoskeletal Transplant Foundation Inc. | 2 | $147 |
| Stryker(2 entities) | 4 | $111 |
| AbbVie | 1 | $19 |
| Globus Medical | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,703 in reported general payments places this provider in the 65th percentile of 40 foot & ankle surgery providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Febuxostat | 65 | $8,278 |
| SantylCollagenase Clostridium Hist. | 18 | $6,981 |
| Gabapentin | 312 | $6,432 |
| Nitroglycerin PatchNitroglycerin | 115 | $5,945 |
| Ciclopirox | 188 | $5,484 |
| Cefdinir | 215 | $3,930 |
| Nystatin | 183 | $3,697 |
| Pregabalin | 37 | $3,427 |
| Diclofenac Sodium | 135 | $3,138 |
| Allopurinol | 219 | $2,569 |
| Pentoxifylline | 49 | $2,270 |
| Cilostazol | 71 | $1,756 |
| ClopidogrelClopidogrel Bisulfate | 79 | $1,250 |
| Enoxaparin Sodium | 17 | $860 |
| Duloxetine Hcl | 30 | $753 |
Paid to pharmacies, not to this prescriber.
Other foot & ankle surgery in Montrose
- Norman WaldropBirmingham$3.6M
- Justin DaigreDecatur$372K
- John KirchnerHoover$84K
- Jefferson SabatiniHuntsville$56K
- Matthew DeorioHuntsville$49K
- Patricia AnteroTuscaloosa$35K
- Ashish ShahBirmingham$28K
- Alfred RicciMontgomery$25K
- Swapnil SinghBirmingham$14K
- Derek KlavasMobile$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.